EGFR-mutant Non-small Cell Lung Cancer Not Yet Recruiting Phase 2 Trials for Famitinib (DB11741)

IndicationStatusPhase
DBCOND0092543 (EGFR-mutant Non-small Cell Lung Cancer)Not Yet Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03904823A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLCTreatment